O	0	3	The
O	4	12	efficacy
O	13	16	and
O	17	23	safety
O	24	26	of
B-intervention	27	38	neoadjuvant
I-intervention	39	51	chemotherapy
I-intervention	52	53	+
I-intervention	53	54	/
I-intervention	54	55	-
I-intervention	56	65	letrozole
O	66	68	in
O	69	83	postmenopausal
O	84	89	women
O	90	94	with
O	95	102	locally
O	103	111	advanced
O	112	118	breast
O	119	125	cancer
O	125	126	:
O	127	128	a
O	129	139	randomized
O	140	145	phase
O	146	149	III
O	150	158	clinical
O	159	164	trial
O	164	165	.

O	166	170	This
O	171	174	two
O	174	175	-
O	175	178	arm
O	179	189	randomized
O	190	198	clinical
O	199	204	study
O	205	210	aimed
O	211	213	to
O	214	222	evaluate
O	223	226	the
O	227	235	efficacy
O	236	239	and
O	240	246	safety
O	247	249	of
O	250	261	neoadjuvant
O	262	272	concurrent
O	273	285	chemotherapy
O	286	289	and
O	290	299	letrozole
O	300	302	in
O	303	317	postmenopausal
O	318	323	women
O	324	328	with
O	329	336	locally
O	337	345	advanced
O	346	352	breast
O	353	362	carcinoma
O	362	363	.

B-total-participants	364	367	One
I-total-participants	368	375	hundred
I-total-participants	376	379	and
I-total-participants	380	383	one
O	384	398	postmenopausal
O	399	404	women
O	405	409	aged
B-age	410	412	50
I-age	412	413	-
I-age	413	415	83
I-age	416	421	years
B-eligibility	422	426	with
I-eligibility	427	441	pathologically
I-eligibility	442	448	proven
I-eligibility	449	456	locally
I-eligibility	457	465	advanced
I-eligibility	466	467	(
I-eligibility	467	475	clinical
I-eligibility	476	481	stage
I-eligibility	482	484	T3
I-eligibility	484	485	,
I-eligibility	486	488	T4
I-eligibility	489	492	and
I-eligibility	492	493	/
I-eligibility	493	495	or
I-eligibility	496	498	N2
I-eligibility	498	499	,
I-eligibility	500	502	N3
I-eligibility	502	503	)
I-eligibility	504	510	breast
I-eligibility	511	517	cancer
O	518	522	were
O	523	531	randomly
O	532	540	assigned
O	541	543	to
O	544	551	receive
O	552	563	neoadjuvant
B-control	564	576	chemotherapy
I-control	577	582	alone
I-control	583	584	(
I-control	584	591	control
I-control	592	595	arm
O	595	596	,
O	597	598	n
O	599	600	=
B-control-participants	601	603	51
O	603	604	)
O	605	607	or
O	608	619	neoadjuvant
O	620	632	chemotherapy
O	633	643	concurrent
O	644	648	with
O	649	658	letrozole
O	659	660	2
O	660	661	.
O	661	662	5
O	663	665	mg
O	666	667	(
O	667	672	study
O	673	676	arm
O	676	677	,
O	678	679	n
O	680	681	=
B-intervention-participants	682	684	50
O	684	685	)
O	685	686	.

O	687	699	Chemotherapy
O	700	709	consisted
O	710	712	of
O	713	714	a
O	715	721	median
O	722	723	4
O	724	725	(
O	725	730	range
O	731	732	3
O	732	733	-
O	733	734	5
O	734	735	)
O	736	742	cycles
O	743	745	of
O	746	757	intravenous
O	758	759	5
O	759	760	-
O	760	772	fluorouracil
O	773	776	600
O	777	779	mg
O	779	780	/
O	780	781	m
O	781	782	(
O	782	783	2
O	783	784	)
O	784	785	,
O	786	797	doxorubicin
O	798	800	60
O	801	803	mg
O	803	804	/
O	804	805	m
O	805	806	(
O	806	807	2
O	807	808	)
O	808	809	,
O	810	813	and
O	814	830	cyclophosphamide
O	831	834	600
O	835	837	mg
O	837	838	/
O	838	839	m
O	839	840	(
O	840	841	2
O	841	842	)
O	842	843	,
O	844	849	every
O	850	855	three
O	856	861	weeks
O	861	862	.

O	863	866	All
O	867	875	patients
O	876	888	subsequently
O	889	898	underwent
O	899	907	modified
O	908	915	radical
O	916	926	mastectomy
O	927	940	approximately
O	941	944	two
O	945	950	weeks
O	951	956	after
O	957	960	the
O	961	965	last
O	966	971	cycle
O	972	974	of
O	975	987	chemotherapy
O	987	988	.

B-outcome	989	999	Pathologic
I-outcome	1000	1008	complete
I-outcome	1009	1017	response
I-outcome	1018	1023	rates
O	1024	1028	were
B-iv-bin-percent	1029	1031	25
I-iv-bin-percent	1031	1032	.
I-iv-bin-percent	1032	1033	5
I-iv-bin-percent	1033	1034	%
O	1035	1038	and
B-cv-bin-percent	1039	1041	10
I-cv-bin-percent	1041	1042	.
I-cv-bin-percent	1042	1043	2
I-cv-bin-percent	1043	1044	%
O	1045	1047	in
O	1048	1051	the
O	1052	1057	study
O	1058	1061	and
O	1062	1065	the
O	1066	1073	control
O	1074	1079	group
O	1079	1080	,
O	1081	1093	respectively
O	1094	1095	(
O	1095	1096	P
O	1097	1098	=
O	1099	1100	0
O	1100	1101	.
O	1101	1104	049
O	1104	1105	)
O	1105	1106	.

O	1107	1116	Similarly
O	1116	1117	,
B-outcome	1118	1126	clinical
I-outcome	1127	1135	complete
I-outcome	1136	1144	response
I-outcome	1145	1150	rates
O	1151	1155	were
B-iv-bin-percent	1156	1158	27
I-iv-bin-percent	1158	1159	.
I-iv-bin-percent	1159	1160	6
I-iv-bin-percent	1160	1161	%
O	1162	1165	and
B-cv-bin-percent	1166	1168	10
I-cv-bin-percent	1168	1169	.
I-cv-bin-percent	1169	1170	2
I-cv-bin-percent	1170	1171	%
O	1172	1174	in
O	1175	1178	the
O	1179	1184	study
O	1185	1188	and
O	1189	1192	the
O	1193	1200	control
O	1201	1206	group
O	1206	1207	,
O	1208	1220	respectively
O	1221	1222	(
O	1222	1223	P
O	1224	1225	=
O	1226	1227	0
O	1227	1228	.
O	1228	1231	037
O	1231	1232	)
O	1232	1233	.

O	1234	1236	In
O	1237	1240	the
O	1241	1249	subgroup
O	1250	1258	analysis
O	1259	1261	of
O	1262	1269	hormone
O	1270	1278	receptor
O	1278	1279	-
O	1279	1287	positive
O	1288	1293	cases
O	1293	1294	,
O	1295	1298	the
O	1299	1307	complete
O	1308	1316	response
O	1317	1322	rates
O	1323	1327	were
O	1328	1332	more
O	1333	1342	prominent
O	1343	1345	in
O	1346	1351	study
O	1352	1357	group
O	1358	1366	compared
O	1367	1371	with
O	1372	1379	control
O	1380	1385	group
O	1385	1386	.

O	1387	1393	Common
O	1394	1403	treatment
O	1403	1404	-
O	1404	1411	related
O	1412	1416	side
O	1417	1424	effects
O	1425	1429	such
O	1430	1432	as
B-outcome	1433	1439	nausea
O	1439	1440	,
B-outcome	1441	1449	vomiting
O	1449	1450	,
B-outcome	1451	1455	bone
I-outcome	1456	1462	marrow
I-outcome	1463	1474	suppression
O	1474	1475	,
O	1476	1479	and
B-outcome	1480	1489	mucositis
O	1490	1494	were
O	1495	1502	similar
O	1503	1505	in
O	1506	1510	both
O	1511	1517	groups
O	1517	1518	,
O	1519	1522	but
B-outcome	1523	1526	hot
I-outcome	1527	1532	flush
O	1533	1536	was
O	1537	1541	more
O	1542	1551	prevalent
O	1552	1554	in
O	1555	1560	study
O	1561	1566	group
O	1567	1575	compared
O	1576	1580	with
O	1581	1588	control
O	1589	1594	group
O	1595	1596	(
O	1596	1597	P
O	1598	1599	=
O	1600	1601	0
O	1601	1602	.
O	1602	1605	023
O	1605	1606	)
O	1606	1607	.

O	1608	1611	The
O	1612	1620	addition
O	1621	1623	of
O	1624	1633	letrozole
O	1634	1646	concurrently
O	1647	1651	with
O	1652	1663	neoadjuvant
O	1664	1676	chemotherapy
O	1677	1685	provides
O	1686	1687	a
O	1688	1694	higher
O	1695	1703	clinical
O	1704	1707	and
O	1708	1718	pathologic
O	1719	1727	response
O	1728	1733	rates
O	1734	1738	with
O	1739	1749	acceptable
O	1750	1758	toxicity
O	1759	1767	compared
O	1768	1772	with
O	1773	1785	chemotherapy
O	1786	1791	alone
O	1792	1794	in
O	1795	1809	postmenopausal
O	1810	1815	women
O	1816	1820	with
O	1821	1828	locally
O	1829	1837	advanced
O	1838	1847	sensitive
O	1848	1854	breast
O	1855	1861	cancer
O	1861	1862	.
